Cargando…
Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice
Little observational data exist describing telbivudine (LdT) or lamivudine (LAM) use in late pregnancy for preventing hepatitis B mother-to-child transmission (MTCT) in real-world settings. During the period of January 2009 to March 2011, we enrolled hepatitis B e antigen–positive mothers with HBV D...
Autores principales: | Zhang, Hua, Pan, Calvin Q, Pang, Qiumei, Tian, Ruihua, Yan, Miaoe, Liu, Xin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282428/ https://www.ncbi.nlm.nih.gov/pubmed/25187919 http://dx.doi.org/10.1002/hep.27034 |
Ejemplares similares
-
Estimation of hepatitis C virus infections resulting from vertical transmission in Egypt
por: Benova, Lenka, et al.
Publicado: (2015) -
Predicting hepatitis B e Antigen seroconversion after pregnancy—The SydPregScore
por: Thilakanathan, Cynthuja, et al.
Publicado: (2022) -
Factors associated with treatment failure of direct‐acting antivirals for chronic hepatitis C: A real‐world nationwide hepatitis C virus registry programme in Taiwan
por: Chen, Chi‐Yi, et al.
Publicado: (2021) -
Maternal and fetal outcomes of pregnancies complicated by acute hepatitis E and the impact of HIV status: A cross‐sectional study in Namibia
por: Heemelaar, Steffie, et al.
Publicado: (2021) -
Forecasting Hepatitis C liver disease burden on real‐life data. Does the hidden iceberg matter to reach the elimination goals?
por: Kondili, Loreta A., et al.
Publicado: (2018)